{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:14:50Z","timestamp":1749701690441,"version":"3.41.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1097\/tp.0000000000001543","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T11:58:56Z","timestamp":1477396736000},"page":"2218-2227","source":"Crossref","is-referenced-by-count":3,"title":["Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression"],"prefix":"10.1097","volume":"101","author":[{"given":"Dae Hae","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Keymeulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Hilbrands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhidong","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursule","family":"Van de Velde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Jacobs-Tulleneers-Thevissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"Maleux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Lapauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Crenier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"De Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pipeleers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-48-20210211","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5500\/wjt.v3.i4.48","article-title":"Current status of clinical islet transplantation","volume":"3","author":"Pepper","year":"2013","journal-title":"World J Transplant"},{"key":"R2-48-20210211","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/dc15-0094","article-title":"Five-year metabolic, functional, and safety results of patients with type 1 diabetes transplanted with allogenic islets within the Swiss-French GRAGIL network","volume":"38","author":"Lablanche","year":"2015","journal-title":"Diabetes Care"},{"key":"R3-48-20210211","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.2337\/dc15-0090","article-title":"Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia","volume":"38","author":"Choudhary","year":"2015","journal-title":"Diabetes Care"},{"key":"R4-48-20210211","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2337\/diabetes.54.7.2060","article-title":"Five-year follow-up after clinical islet transplantation","volume":"54","author":"Ryan","year":"2005","journal-title":"Diabetes"},{"key":"R5-48-20210211","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/j.1600-6143.2005.00957.x","article-title":"Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience","volume":"5","author":"Froud","year":"2005","journal-title":"Am J Transplant"},{"key":"R6-48-20210211","doi-asserted-by":"crossref","first-page":"17444","DOI":"10.1073\/pnas.0608141103","article-title":"Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft","volume":"103","author":"Keymeulen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R7-48-20210211","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc08-1685","article-title":"Primary graft function, metabolic control, and graft survival after islet transplantation","volume":"32","author":"Vantyghem","year":"2009","journal-title":"Diabetes Care"},{"key":"R8-48-20210211","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1111\/ajt.12469","article-title":"Attainment of metabolic goals in the integrated UK Islet Transplant Program with locally isolated and transported preparations","volume":"13","author":"Brooks","year":"2013","journal-title":"Am J Transplant"},{"key":"R10-48-20210211","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s001250050929","article-title":"Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft","volume":"41","author":"Keymeulen","year":"1998","journal-title":"Diabetologia"},{"key":"R11-48-20210211","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1432-2277.2003.tb00284.x","article-title":"Laparoscopic approach for human islet transplantation into a defined liver segment in type-1 diabetic patients","volume":"16","author":"Movahedi","year":"2003","journal-title":"Transpl Int"},{"key":"R12-48-20210211","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1097\/01.RVI.0000182506.88739.39","article-title":"Feasibility, safety, and efficacy of percutaneous transhepatic injection of beta-cell grafts","volume":"16","author":"Maleux","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"R13-48-20210211","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/TP.0b013e3181c478fd","article-title":"Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success","volume":"89","author":"Koh","year":"2010","journal-title":"Transplantation"},{"key":"R16-48-20210211","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc08-1987","article-title":"New definition for the partial remission period in children and adolescents with type 1 diabetes","volume":"32","author":"Mortensen","year":"2009","journal-title":"Diabetes Care"},{"key":"R17-48-20210211","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1097\/01.tp.0000187881.97068.77","article-title":"Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation","volume":"80","author":"Hafiz","year":"2005","journal-title":"Transplantation"},{"key":"R18-48-20210211","doi-asserted-by":"crossref","first-page":"E471","DOI":"10.1111\/ctr.12011","article-title":"Safety and tolerability of the T cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation","volume":"26","author":"Takita","year":"2012","journal-title":"Clin Transplant"},{"key":"R19-48-20210211","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/TP.0000000000000217","article-title":"Single-donor islet transplantation and long-term insulin independence in select patients with type 1 diabetes mellitus","volume":"98","author":"Al-Adra","year":"2014","journal-title":"Transplantation"},{"key":"R20-48-20210211","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00592-014-0627-6","article-title":"Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience","volume":"51","author":"Qi","year":"2014","journal-title":"Acta Diabetol"},{"key":"R21-48-20210211","first-page":"4","article-title":"Islet transplantation at the Dresden Diabetes Center: five years' experience","volume":"47","author":"Ludwig","year":"2015","journal-title":"Horm Metab Res"},{"key":"R22-48-20210211","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.2337\/db12-1802","article-title":"Improvement in \u03b2-cell secretory capacity after human islet transplantation according to the CIT07 Protocol","volume":"62","author":"Rickels","year":"2013","journal-title":"Diabetes"},{"key":"R23-48-20210211","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1111\/ajt.12250","article-title":"Multicenter Australian Trial of Islet Transplantation: improving accessibility and outcomes","volume":"13","author":"Consortium","year":"2013","journal-title":"Am J Transplant"},{"key":"R24-48-20210211","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/TP.0000000000000458","article-title":"Impact of procedure-related complications on long-term islet transplantation outcome","volume":"99","author":"Caiazzo","year":"2015","journal-title":"Transplantation"},{"key":"R25-48-20210211","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1016\/j.transproceed.2014.09.155","article-title":"Gastrointestinal disorders after renal transplantation","volume":"46","author":"Savvidaki","year":"2014","journal-title":"Transplant Proc"},{"key":"R26-48-20210211","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0012.1997.tb00823.x","article-title":"Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group","volume":"11","author":"Gruessner","year":"1997","journal-title":"Clin Transplant"},{"key":"R27-48-20210211","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/00007890-199808150-00007","article-title":"Mycophenolate mofetil in pancreas transplantation","volume":"66","author":"Gruessner","year":"1998","journal-title":"Transplantation"},{"key":"R28-48-20210211","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/1744666X.2016.1123093","article-title":"Tacrolimus for the prevention and treatment of rejection of solid organ transplants","volume":"12","author":"Scalea","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"R29-48-20210211","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/TP.0b013e318277e378","article-title":"Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation","volume":"95","author":"Guethoff","year":"2013","journal-title":"Transplantation"},{"key":"R30-48-20210211","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1464-5491.2009.02731.x","article-title":"Quality of life after islet transplantation: data from the GRAGIL 1 and 2 trials","volume":"26","author":"Benhamou","year":"2009","journal-title":"Diabet Med"},{"key":"R31-48-20210211","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/01.tp.0000280550.01028.89","article-title":"Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome","volume":"84","author":"Toso","year":"2007","journal-title":"Transplantation"},{"key":"R32-48-20210211","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-6143.2005.01174.x","article-title":"Quality of life after islet transplantation","volume":"6","author":"Poggioli","year":"2006","journal-title":"Am J Transplant"},{"key":"R33-48-20210211","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1034\/j.1600-6143.2003.00160.x","article-title":"Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation","volume":"3","author":"Kaufman","year":"2003","journal-title":"Am J Transplant"},{"key":"R34-48-20210211","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/diacare.29.04.06.dc05-1647","article-title":"Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients","volume":"29","author":"Huurman","year":"2006","journal-title":"Diabetes Care"},{"key":"R35-48-20210211","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1111\/j.1600-6143.2011.03724.x","article-title":"Late cytomegalovirus transmission and impact of T-depletion in clinical islet transplantation","volume":"11","author":"Gala-Lopez","year":"2011","journal-title":"Am J Transplant"},{"key":"R36-48-20210211","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/j.1600-6143.2004.00557.x","article-title":"Cytomegalovirus prevalence and transmission after islet allograft transplant in patients with type 1 diabetes mellitus","volume":"4","author":"Hafiz","year":"2004","journal-title":"Am J Transplant"},{"key":"R37-48-20210211","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1097\/01.TP.0000142619.01510.A5","article-title":"Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients","volume":"78","author":"Freeman","year":"2004","journal-title":"Transplantation"},{"key":"R38-48-20210211","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1600-6143.2004.00391.x","article-title":"Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+\/R\u2212 solid organ transplant recipients","volume":"4","author":"Humar","year":"2004","journal-title":"Am J Transplant"},{"key":"R39-48-20210211","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1600-6143.2005.00797.x","article-title":"Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+\/R- transplant recipients","volume":"5","author":"Humar","year":"2005","journal-title":"Am J Transplant"},{"key":"R40-48-20210211","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"R41-48-20210211","doi-asserted-by":"crossref","first-page":"a015677","DOI":"10.1101\/cshperspect.a015677","article-title":"Cancer in the transplant recipient","volume":"3","author":"Chapman","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R42-48-20210211","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"R43-48-20210211","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/TP.0000000000000086","article-title":"Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy","volume":"98","author":"Gillard","year":"2014","journal-title":"Transplantation"},{"key":"R44-48-20210211","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.diabet.2013.10.003","article-title":"Treating diabetes with islet transplantation: lessons from the past decade in Lille","volume":"40","author":"Vantyghem","year":"2014","journal-title":"Diabetes Metab"},{"key":"R45-48-20210211","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/TP.0b013e31815e8926","article-title":"Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts","volume":"85","author":"Gillard","year":"2008","journal-title":"Transplantation"},{"key":"R46-48-20210211","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.2337\/dc15-1188","article-title":"Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis","volume":"38","author":"Gorst","year":"2015","journal-title":"Diabetes Care"},{"key":"R47-48-20210211","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/dia.2009.0043","article-title":"The assessment of glycemic variability and its impact on diabetes-related complications: an overview","volume":"11","author":"Weber","year":"2009","journal-title":"Diabetes Technol Ther"},{"key":"R48-48-20210211","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dc13-2112","article-title":"The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview","volume":"37","author":"Nathan","year":"2014","journal-title":"Diabetes Care"},{"key":"R49-48-20210211","first-page":"977","article-title":"The Diabetes Control and Complications Trial Research Group.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"R50-48-20210211","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/SLA.0b013e3181f65c7d","article-title":"The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome","volume":"252","author":"Tullius","year":"2010","journal-title":"Ann Surg"},{"key":"R51-48-20210211","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/01.TP.0000438199.76531.4a","article-title":"Graft failure due to noncompliance among 628 kidney transplant recipients with long-term follow-up: a single-center observational study","volume":"97","author":"Gaynor","year":"2014","journal-title":"Transplantation"},{"key":"R52-48-20210211","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.healun.2011.05.007","article-title":"Adherence to immunosuppression in adult lung transplant recipients: prevalence and risk factors","volume":"30","author":"Bosma","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R53-48-20210211","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/01.TP.0000098905.86445.0F","article-title":"Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation","volume":"76","author":"Moberg","year":"2003","journal-title":"Transplantation"},{"key":"R54-48-20210211","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.transproceed.2004.04.028","article-title":"Low-molecular weight dextran sulfate abrogates the instant blood-mediated inflammatory reaction induced by adult porcine islets both in vitro and in vivo","volume":"36","author":"Goto","year":"2004","journal-title":"Transplant Proc"},{"key":"R55-48-20210211","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2337\/diabetes.51.6.1779","article-title":"Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets possible application of the thrombin inhibitor melagatran in clinical islet transplantation","volume":"51","author":"\u00d6zmen","year":"2002","journal-title":"Diabetes"},{"key":"R56-48-20210211","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/db07-0358","article-title":"Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation","volume":"56","author":"Cabric","year":"2007","journal-title":"Diabetes"},{"key":"R57-48-20210211","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nbt1393","article-title":"Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo","volume":"26","author":"Kroon","year":"2008","journal-title":"Nat Biotechnol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000001543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T20:54:50Z","timestamp":1749675290000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201709000-00048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000001543","relation":{},"ISSN":["0041-1337"],"issn-type":[{"type":"print","value":"0041-1337"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}